| scholarly article | Q13442814 |
| P50 | author | Rafael Rosell | Q30003989 |
| Ramaswamy Govindan | Q59526758 | ||
| Giorgio Scagliotti | Q87768560 | ||
| Silvia Novello | Q104693149 | ||
| P2093 | author name string | Julie R Brahmer | |
| Paulina Selaru | |||
| Heidi H Gillenwater | |||
| Mark A Socinski | |||
| Chandra P Belani | |||
| James N Atkins | |||
| Jose M Sanchez | |||
| Cinta Pallares | |||
| Lesley Tye | |||
| Richard C Chao | |||
| P2860 | cites work | Global cancer statistics, 2002 | Q27860562 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 | ||
| Angiogenesis inhibitors in the treatment of lung cancer | Q34461788 | ||
| Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy | Q34547495 | ||
| Sunitinib in patients with metastatic renal cell carcinoma | Q34568166 | ||
| Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer | Q39714055 | ||
| Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas | Q40384762 | ||
| SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer | Q40647641 | ||
| Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer | Q43202368 | ||
| SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo | Q44280921 | ||
| In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. | Q44285254 | ||
| SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model | Q44720331 | ||
| Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
| Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma | Q46837791 | ||
| Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy | Q53521886 | ||
| Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group | Q54048009 | ||
| Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer | Q73513573 | ||
| Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 | Q83862094 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| multicenter clinical trial | Q6934595 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 650-656 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer | |
| P478 | volume | 26 |
| Q33407426 | A Phase I Trial of Sunitinib and Rapamycin in Patients with Advanced Non-Small Cell Lung Cancer |
| Q33397590 | A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer |
| Q34250125 | A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours |
| Q54621891 | A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. |
| Q33398787 | A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study |
| Q43279004 | A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. |
| Q54656439 | A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. |
| Q35135727 | A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma |
| Q33408559 | A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). |
| Q41876315 | Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer |
| Q40322647 | Acute renal failure after treatment with sunitinib in a patient with multiple myeloma |
| Q36161541 | Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer |
| Q33708516 | Amplification of chromosomal segment 4q12 in non-small cell lung cancer |
| Q38077494 | An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents |
| Q37977440 | Ancillary testing in lung cancer diagnosis |
| Q37435385 | Angiogenesis in the treatment of non-small cell lung cancer |
| Q37138254 | Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC). |
| Q54524450 | Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities |
| Q34821321 | Anti-angiogenic agents in the treatment of non-small cell lung cancer |
| Q37688711 | Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? |
| Q36563542 | Antiangiogenic Therapy for Cancer: An Update |
| Q38153445 | Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective |
| Q37981514 | Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer |
| Q34854658 | Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. |
| Q38000486 | Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? |
| Q36354404 | Aptamer-nanoparticle assembly for logic-based detection |
| Q38085684 | Axitinib for the treatment of advanced non-small-cell lung cancer |
| Q38116094 | BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer |
| Q38627885 | Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib |
| Q37796083 | Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer |
| Q37773367 | Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development. |
| Q37980593 | Beyond Bevacizumab: Antiangiogenic Agents |
| Q43077944 | Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact |
| Q37921797 | Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look? |
| Q53265222 | Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration |
| Q43179458 | Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy |
| Q34836398 | CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer |
| Q35346619 | Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors |
| Q37895767 | Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer |
| Q33988445 | Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial |
| Q37614566 | Chemotherapy for lung cancer: the state of the art in 2009. |
| Q38956300 | Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence |
| Q47305390 | Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. |
| Q37613493 | Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? |
| Q38091669 | Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis |
| Q37961338 | Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists |
| Q54548367 | Current status and future direction of multi-targeted drugs in the era of personalized therapy--overview of advances in multi-targeted therapy in non-small cell lung cancer |
| Q37944183 | Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC) |
| Q38160089 | EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. |
| Q37945645 | Emerging antiangiogenic therapies for non-small-cell lung cancer |
| Q33429478 | Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer |
| Q37269316 | Emerging options for the management of non-small cell lung cancer |
| Q36482542 | Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer |
| Q37624187 | Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected]. |
| Q37788981 | Examining the safety profile of angiogenesis inhibitors: implications for clinical practice |
| Q36920386 | Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung |
| Q42861119 | Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib |
| Q35751860 | Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors |
| Q42738385 | Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors |
| Q37512962 | Focus on Nintedanib in NSCLC and Other Tumors |
| Q33777454 | Genomics of Squamous Cell Lung Cancer |
| Q36822204 | HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer |
| Q37286696 | HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice |
| Q35572636 | Human urothelial carcinoma cell response to Sunitinib malate therapy in vitro |
| Q34522899 | Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions |
| Q34458274 | Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics |
| Q44785223 | Impact of Different Standardized Uptake Value Measures on PET-Based Quantification of Treatment Response |
| Q37512570 | Investigational agents in the management of non-small cell lung cancer. |
| Q36805595 | KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib |
| Q39861042 | Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors |
| Q37912594 | Lung cancer associated venous thromboembolic disease: A comprehensive review |
| Q34541960 | Lung cancer therapeutics that target signaling pathways: an update |
| Q46049056 | Lung cancer: New biological insights and recent therapeutic advances |
| Q33439007 | Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). |
| Q36709236 | Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients |
| Q42986109 | Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. |
| Q37870920 | Motesanib and advanced NSCLC: experiences and expectations |
| Q38245669 | Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer |
| Q38389986 | Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy |
| Q54500129 | Multitargeted Tyrosine Kinase Inhibitors in Unselected Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC): Impressions From MONET (the Motesanib NSCLC Efficacy and Tolerability Study) |
| Q37992335 | Multitargeted anti-angiogenic agents and NSCLC: Clinical update and future directions |
| Q37884982 | Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer |
| Q36766221 | Neurotoxicity of biologically targeted agents in pediatric cancer trials |
| Q38014533 | New Oral Multitargeted Antiangiogenics in Non-Small-Cell Lung Cancer Treatment |
| Q35660763 | New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond |
| Q37357304 | New avenues for second-line treatment of metastatic non-small-cell lung cancer |
| Q35667806 | New molecular targeted therapies for advanced non-small-cell lung cancer |
| Q38193571 | Nintedanib for the treatment of non-small-cell lung cancer |
| Q35584543 | Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review |
| Q37038500 | Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions |
| Q28386773 | Novel insights into the molecular origins and treatment of lung cancer |
| Q37984612 | Novel targets for VEGF-independent anti-angiogenic drugs. |
| Q33633424 | Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients |
| Q37855233 | Personalized Treatment of Lung Cancer |
| Q37799826 | Personalized medicine for non-small-cell lung cancer. |
| Q43271774 | Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function |
| Q51374826 | Pharmacokinetics, Distribution, and Metabolism of [14C]Sunitinib in Rats, Monkeys, and Humans |
| Q35986273 | Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer |
| Q33396181 | Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma |
| Q33407676 | Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer |
| Q35584072 | Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer |
| Q37424049 | Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer |
| Q42605314 | Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer |
| Q33389519 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer |
| Q45957719 | Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. |
| Q33404543 | Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors |
| Q43424854 | Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. |
| Q35187806 | Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer |
| Q35883400 | Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib |
| Q39816573 | Prospective analysis on survival outcomes of nonsmall cell lung cancer stages over IIIb treated with HangAm-Dan |
| Q35050210 | Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC |
| Q37789579 | Recent Development of Molecular-Targeted Drugs in Lung Cancer |
| Q21092930 | Recent advances of novel targeted therapy in non-small cell lung cancer |
| Q38130137 | Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lung |
| Q49169495 | Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors |
| Q36481247 | Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab |
| Q35076198 | Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancer |
| Q37600496 | Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials |
| Q37679981 | Role of epidermal growth factor receptor in lung cancer and targeted therapies |
| Q37953162 | Safety Profile and Tolerability of Antiangiogenic Agents in Non–Small-Cell Lung Cancer |
| Q38630725 | Safety and efficacy of targeted agents monotherapy in advanced NSCLC. |
| Q37579650 | Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs |
| Q37760357 | Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? |
| Q34280051 | Side effects of anti-angiogenic drugs |
| Q55476332 | Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients. |
| Q33409913 | Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study |
| Q44282851 | Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma |
| Q33996608 | Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study |
| Q33406542 | Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study |
| Q33393174 | Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results |
| Q34005875 | Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience |
| Q44126874 | Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population |
| Q33394774 | Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group |
| Q28245467 | Sunitinib in solid tumors |
| Q33408323 | Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial |
| Q34567910 | Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. |
| Q37226817 | Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis |
| Q39499521 | Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation |
| Q37877012 | Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications |
| Q54411624 | Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung |
| Q36054970 | Targeted therapies for lung cancer: clinical experience and novel agents |
| Q35628597 | Targeted therapies for non-small cell lung cancer: an evolving landscape |
| Q27022852 | Targeted therapies in development for non-small cell lung cancer |
| Q37796392 | Targeted therapies of cancer: Angiogenesis inhibition seems not enough |
| Q38107011 | Targeted therapy with kinase inhibitors in aggressive endocrine tumors |
| Q37781113 | Targeted therapy: an evolving world of lung cancer. |
| Q38964908 | Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. |
| Q37996080 | Targeting VEGF in lung cancer |
| Q37847070 | Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor |
| Q38154236 | Targeting angiogenesis in advanced non-small cell lung cancer |
| Q26861341 | Targeting angiogenesis in squamous non-small cell lung cancer |
| Q35584074 | Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer |
| Q38060389 | Targeting tumor neovasculature in non-small-cell lung cancer |
| Q39799414 | Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines |
| Q36172732 | The Effect of Bevacizumab on Human Malignant Melanoma Cells with Functional VEGF/VEGFR2 Autocrine and Intracrine Signaling Loops |
| Q37809678 | The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer |
| Q36526512 | The VEGF pathway in cancer and disease: responses, resistance, and the path forward. |
| Q92081522 | The biomarkers and potential pathogenesis of lung cancer related cerebral hemorrhage |
| Q36858013 | The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation |
| Q38196755 | The clonal evolution and therapeutic approaches of lung cancer |
| Q54403606 | The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China |
| Q35989994 | The risk for anemia with targeted therapies for solid tumors |
| Q38462638 | The role of anti-angiogenesis in non-small-cell lung cancer: an update |
| Q38268170 | Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview |
| Q55385227 | Tumor angiogenesis and anti-angiogenic gene therapy for cancer. |
| Q38094627 | Tumour vasculature targeting agents in hybrid/conjugate drugs |
| Q37818251 | Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. |
| Q26995385 | Understanding waterfall plots |
| Q33772197 | VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. |
| Q37788428 | Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer |
| Q35939630 | Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer. |
| Q38944457 | Venous Thromboembolism in Patients Diagnosed With Lung Cancer |
| Q47107773 | Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. |
| Q55498918 | [Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer]. |
| Q55464615 | [Progress of platelet derived grow factor family in non-small cell lung cancer]. |
Search more.